ArQule Q2 Loss Narrows, Revenues Rise - Quick Facts

(RTTNews) - Clinical-stage biotechnology company ArQule, Inc. (ARQL) reported that second-quarter net loss narrowed to $4.02 million or $0.06 per share from $6.34 million or $0.10 per share in the prior-year quarter.

On average, three analysts polled by Thomson Reuters expected the company to report a loss of $0.08 per share for the quarter. Analysts' estimates typically exclude special items.

Research and development revenue for the quarter grew to $3.0 billion from $2.90 billion in the same quarter last year, while three analysts had a consensus revenue estimate of $2.50 billion.